Nanoparticle-based drug delivery in the inner ear: current challenges, limitations and opportunities

Rahul Mittal, Stefanie A. Pena, Angela Zhu, Nicolas Eshraghi, Arian Fesharaki, Elijah J. Horesh, Jeenu Mittal, Adrien Eshraghi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Hearing loss is the most common neurosensory impairment worldwide. While conductive hearing loss can be managed by surgery, the management of sensorineural hearing loss (SNHL), related to the damage of sensory cells of the inner ear is more challenging to manage medically. Many causes of SNHL such as sudden idiopathic SNHL, Meniere's disease, noise-induced hearing loss, autoimmune hearing loss or hearing loss from exposure to ototoxic substances can benefit from delivery of otoprotective drugs to the inner ear. However, systemic drug delivery through oral, intravenous and intramuscular methods leads to undesirable side effects due to the inner ear's limited blood supply and the relatively poor penetration of the blood-inner ear barrier (BLB). Therefore, there has been an increased interest for the targeted drug delivery to the inner ear using nanoparticles. Drug delivery through nanoparticles offers several advantages including drug stabilization for controlled release and surface modification for specific targeting. Understanding the biocompatibility of nanoparticles with cochlea and developing novel non-invasive delivery methods will promote the translation of nanoparticle-mediated drug delivery for auditory disorders from bench to bedside.

Original languageEnglish (US)
Pages (from-to)1312-1320
Number of pages9
JournalArtificial cells, nanomedicine, and biotechnology
Volume47
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Audition
Inner Ear
Drug delivery
Nanoparticles
Sensorineural Hearing Loss
Hearing Loss
Pharmaceutical Preparations
Conductive Hearing Loss
Noise-Induced Hearing Loss
Meniere Disease
Blood
Cochlea
Biocompatibility
Acoustic noise
Surgery
Surface treatment
Stabilization

Keywords

  • drug delivery
  • hearing loss
  • inner ear
  • Nanoparticles

ASJC Scopus subject areas

  • Biotechnology
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Pharmaceutical Science

Cite this

Nanoparticle-based drug delivery in the inner ear : current challenges, limitations and opportunities. / Mittal, Rahul; Pena, Stefanie A.; Zhu, Angela; Eshraghi, Nicolas; Fesharaki, Arian; Horesh, Elijah J.; Mittal, Jeenu; Eshraghi, Adrien.

In: Artificial cells, nanomedicine, and biotechnology, Vol. 47, No. 1, 01.12.2019, p. 1312-1320.

Research output: Contribution to journalArticle

Mittal, Rahul ; Pena, Stefanie A. ; Zhu, Angela ; Eshraghi, Nicolas ; Fesharaki, Arian ; Horesh, Elijah J. ; Mittal, Jeenu ; Eshraghi, Adrien. / Nanoparticle-based drug delivery in the inner ear : current challenges, limitations and opportunities. In: Artificial cells, nanomedicine, and biotechnology. 2019 ; Vol. 47, No. 1. pp. 1312-1320.
@article{40e52d752e094c9d81a9c476f368aaed,
title = "Nanoparticle-based drug delivery in the inner ear: current challenges, limitations and opportunities",
abstract = "Hearing loss is the most common neurosensory impairment worldwide. While conductive hearing loss can be managed by surgery, the management of sensorineural hearing loss (SNHL), related to the damage of sensory cells of the inner ear is more challenging to manage medically. Many causes of SNHL such as sudden idiopathic SNHL, Meniere's disease, noise-induced hearing loss, autoimmune hearing loss or hearing loss from exposure to ototoxic substances can benefit from delivery of otoprotective drugs to the inner ear. However, systemic drug delivery through oral, intravenous and intramuscular methods leads to undesirable side effects due to the inner ear's limited blood supply and the relatively poor penetration of the blood-inner ear barrier (BLB). Therefore, there has been an increased interest for the targeted drug delivery to the inner ear using nanoparticles. Drug delivery through nanoparticles offers several advantages including drug stabilization for controlled release and surface modification for specific targeting. Understanding the biocompatibility of nanoparticles with cochlea and developing novel non-invasive delivery methods will promote the translation of nanoparticle-mediated drug delivery for auditory disorders from bench to bedside.",
keywords = "drug delivery, hearing loss, inner ear, Nanoparticles",
author = "Rahul Mittal and Pena, {Stefanie A.} and Angela Zhu and Nicolas Eshraghi and Arian Fesharaki and Horesh, {Elijah J.} and Jeenu Mittal and Adrien Eshraghi",
year = "2019",
month = "12",
day = "1",
doi = "10.1080/21691401.2019.1573182",
language = "English (US)",
volume = "47",
pages = "1312--1320",
journal = "Artificial Cells, Nanomedicine and Biotechnology",
issn = "2169-1401",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Nanoparticle-based drug delivery in the inner ear

T2 - current challenges, limitations and opportunities

AU - Mittal, Rahul

AU - Pena, Stefanie A.

AU - Zhu, Angela

AU - Eshraghi, Nicolas

AU - Fesharaki, Arian

AU - Horesh, Elijah J.

AU - Mittal, Jeenu

AU - Eshraghi, Adrien

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Hearing loss is the most common neurosensory impairment worldwide. While conductive hearing loss can be managed by surgery, the management of sensorineural hearing loss (SNHL), related to the damage of sensory cells of the inner ear is more challenging to manage medically. Many causes of SNHL such as sudden idiopathic SNHL, Meniere's disease, noise-induced hearing loss, autoimmune hearing loss or hearing loss from exposure to ototoxic substances can benefit from delivery of otoprotective drugs to the inner ear. However, systemic drug delivery through oral, intravenous and intramuscular methods leads to undesirable side effects due to the inner ear's limited blood supply and the relatively poor penetration of the blood-inner ear barrier (BLB). Therefore, there has been an increased interest for the targeted drug delivery to the inner ear using nanoparticles. Drug delivery through nanoparticles offers several advantages including drug stabilization for controlled release and surface modification for specific targeting. Understanding the biocompatibility of nanoparticles with cochlea and developing novel non-invasive delivery methods will promote the translation of nanoparticle-mediated drug delivery for auditory disorders from bench to bedside.

AB - Hearing loss is the most common neurosensory impairment worldwide. While conductive hearing loss can be managed by surgery, the management of sensorineural hearing loss (SNHL), related to the damage of sensory cells of the inner ear is more challenging to manage medically. Many causes of SNHL such as sudden idiopathic SNHL, Meniere's disease, noise-induced hearing loss, autoimmune hearing loss or hearing loss from exposure to ototoxic substances can benefit from delivery of otoprotective drugs to the inner ear. However, systemic drug delivery through oral, intravenous and intramuscular methods leads to undesirable side effects due to the inner ear's limited blood supply and the relatively poor penetration of the blood-inner ear barrier (BLB). Therefore, there has been an increased interest for the targeted drug delivery to the inner ear using nanoparticles. Drug delivery through nanoparticles offers several advantages including drug stabilization for controlled release and surface modification for specific targeting. Understanding the biocompatibility of nanoparticles with cochlea and developing novel non-invasive delivery methods will promote the translation of nanoparticle-mediated drug delivery for auditory disorders from bench to bedside.

KW - drug delivery

KW - hearing loss

KW - inner ear

KW - Nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=85064926408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064926408&partnerID=8YFLogxK

U2 - 10.1080/21691401.2019.1573182

DO - 10.1080/21691401.2019.1573182

M3 - Article

C2 - 30987439

AN - SCOPUS:85064926408

VL - 47

SP - 1312

EP - 1320

JO - Artificial Cells, Nanomedicine and Biotechnology

JF - Artificial Cells, Nanomedicine and Biotechnology

SN - 2169-1401

IS - 1

ER -